Anplag

Anplag is a South Korean biotechnology company focused on developing disease-modifying therapies for neurodegenerative disorders. The company specializes in the discovery of small molecule inhibitors that target the aggregation of pathogenic proteins, such as alpha-synuclein and amyloid-beta. By utilizing a proprietary screening platform, Anplag identifies candidates that can prevent the formation of toxic protein clumps and potentially dissolve existing aggregates. Their lead programs are currently in the pre-clinical stage, targeting high-impact conditions including Parkinson's disease and Alzheimer's disease. Anplag aims to address the root causes of proteopathy to provide transformative treatments for patients with limited options.